semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Dyslipidemias Age 18 to 80 years. 2. Dyslipidemia with LDL-C At screening if untreated: 100 to 190 mg/dL At screening if treated with statins or other lipid-lowering drugs: 100 to 170 mg/dL At start of double-blind treatment: 100 to 190 mg/dL. 3. HDL-C <45 mg/dL (males) or <50 mg/dL (females). 4. Fasting TG <400 mg/dL. 5. Presence of the following conditions is permitted but not mandatory, at the discretion of the investigator Treated and stable coronary heart disease without acute events in the past 3 months and stable, state-of-the-art medication Treated and stable carotid artery disease or peripheral arterial disease on stable, standard medication for the past 3 months Treated and stable Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤9.5%. 6. Willing and able to sign the informed consent form (ICF)  Chronic heart failure as defined by New York Heart Association classes III and IV. 2. Uncontrolled cardiac arrhythmias. 3. Myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, or unstable angina in past 3 months before Visit 1. 4. Stroke or transient ischemic attack within 3 months before Visit 1. 5. Uncontrolled hypertension. 6. Clinically significant laboratory abnormalities Aspartate aminotransferase or alanine aminotransferase >2 times upper limit of normal range Bilirubin >1.5 times upper limit of normal range Creatine kinase >2 times upper limit of normal range. 7. Any active nephropathy or estimated glomerular filtration rate <60 mL/min/1.73m2 or on kidney dialysis. 8. Poorly controlled (thyroid-stimulating hormone [TSH] >2 times upper limit of normal) hyperthyroidism. 9. Homozygous familial hypercholesterolemia. 10. Intolerance or hypersensitivity to atorvastatin or rosuvastatin. 11. Prior treatment with any CETP inhibitor. 12. Positive for human immunodeficiency virus (HIV) positive, hepatitis B or hepatitis C
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 31.0-70.0,  PreDiabetes 30<Age<71 2. BMI≥23 kg/m2 3. '75g Oral glucose tolerance 2 hours after the test Blood glucose140~199mg/dL' or 'Fasting Blood Sugar 110~125 mg/dL' or 'HbA1c 5.7%~6.4%'  Who diagnosed with Diabetes Mellitus or Who having Drugs for Diabetes Mellitus. 2. Type 2 Diabetes Mellitus Who diagnosed with Diabetes Mellitus except for maternity period Who have had drugs for Diabetes Mellitus(hypoglycemic agent or insulin) except for maternity period Fasting Glucose≥ 126 mg/dL Oral glucose tolerance 2 hours after the Blood glucose ≥ 200 mg/dL HbA1c ≥ 6.5% 3. Who life expectancy is short Cardiac history History of severe cardiovascular disease within the last 6 months (cerebral hemorrhage, stroke, myocardial infarction, angina pectoris, heart failure, etc.) Systolic blood pressure >180 mmHg or Diastolic blood pressure >105 mmHg aortic stenosis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Heart Failure 80 year, male or female Chronic Heart failure subjects with medical history of cardiac disease or other related cardiovascular disease Left ventricular ejection fraction (LVEF) less than or equal to (=<) 40 percent (%) New York Heart Association (NYHA) class of II NYHA II ： Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation NYHA III：Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation NYHA IV：Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort increased Signed Informed Consent Form (ICF)  Acute coronary syndrome (ACS) within 3 months Under beta-blocker treatment for the last 2 weeks Under other medicine treatment which may affect heart rate, like Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin treatment [more than (>) 0.125 milligram (mg)] Uncontrolled Diabetes [hemoglobin A1c, (HbA1c) >7.5%] Severe or uncontrolled hypertension [resting Systolic Blood Pressure (SBP) >180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) >110mmHg at screening period] Severe hypotension [resting SBP less than (<) 90mmHg, or resting DBP<50mmHg] Resting heart rate <60 beat per minute (bpm) Any contradiction to Bisoprolol according to label, including Acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy Cardiogenic shock
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Prevention Be prescribed with PrEP Male biological sex Age ≥18 years Willing and able to provide written informed consent  Signs or symptoms of acute retroviral syndrome Upon enrollment, having a condition that, based on the opinion of the investigator or designee, prevents the participant from providing informed consent; makes participation in the project unsafe; complicates the interpretation of results; or somehow interferes with the achievement of project objectives
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Heart Failure presentation to hospital with acute dyspnea  refusal to give informed consent; acute coronary syndromes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  DM2 Male & female patient with Known history of DM for more than 3 months before randomization Hospital admission due to blood glucose levels ranging between 180-400 mg/dl Average of two consecutive blood glucose levels above 180 mg/dl Age between 18 and 85 years old Home treatment with diet alone, any combination of oral antidiabetic agents, or insulin therapy at daily dose <0.4 units/kg  BG >400 mg/dl in the period before randomization Prior history of hyperglycemic crises Have hyperglycemia without history of diabetes Patient who expected ICU admission or cardiac surgery A history of pancreatitis, active gallbladder disease, Corticosteroid therapy or hepatic disease Impaired renal function (glomerular filtration rate [GFR] <30 mL/min or serum creatinine ≥3.0 mg/dL) History of diabetic ketoacidosis Pregnancy Inability to give informed consent (poor mental status)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 2 Diabetes Mellitus Insulin Resistance Males Age 18-65 inclusive Established T2DM for ≥ 1 year Taking stable doses (≤ 20% change in total daily insulin dose within 2 months prior to screening) of basal insulin, with or without prandial insulin (total daily dose must be ≤ 200 units) Baseline hemoglobin A1c (HbA1c) 8.0%-10.5% No use of any anti-hyperglycemic agents (oral or injectable) other than metformin or insulin No history or clinical suspicion of type 1 diabetes mellitus No concurrent chronic use of any corticosteroids by any route and for any indication, or concurrent conditions that may require the initiation of glucocorticoids during the study No concurrent lipid-lowering medications whose levels are dependent on CYP3A pathway clearance (e.g., simvastatin, lovastatin, atorvastatin, fluvastatin and rosuvastatin) should either be washed out for at least one month prior to enrollment and/or switched to alternative LDL-cholesterol lowering agents (e.g., pravastatin or ezetimibe) for at least one month No contraindications or known intolerance to mifepristone
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Hemodialysis Hypertension Age > 18 years Dialysis vintage > 3 months A history of hypertension, confirmed by valid Home BP readings Written consent to take part in the study  Cancer or other advanced non cardiac disease or co-morbidity (e.g. end-stage liver failure) imposing a very poor short-term prognosis Active infections or relevant inter-current disease Inadequate lung scanning and echocardiographic studies Hemodynamic instability during dialysis session that require intravenous fluid administration to restore BP, in over 30% of sessions during the past 3 months Patients with modification of their dry weight and antihypertensive treatment during one month prior to study enrolment Nonfunctional arteriovenous fistula in the contralateral arm of the one used as vascular access for the hemodialysis session Patients with Home BP readings >180/110 mmHg Patients with history of drug or alcohol abuse or known severe mental disorder Pregnancy at study entry or during study period
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer A diagnosis of stage IV NSCLC or extensive stage SCLC Self-reported shortness of breath (a score of 2 or greater on the Modified Medical Research Council Dyspnea Scale) Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 (asymptomatic) to 2 (symptomatic and in bed <50% of day) The ability to read and respond to questions English Primary cancer care at the Massachusetts General Hospital (MGH) Cancer Center or Dana-Farber Cancer Institute (DFCI) Age >18 years  Cognitive or psychiatric conditions prohibiting study consent or participation A treating clinician who reports that the patient is inappropriate for the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-69.0,  Obesity Generally healthy subjects (men and women ≥ 18 and ≤ 69 years old) were required to be overweight or obese (BMI ≥ 27 kg/m2 and ≤ 50 kg/m2) to exhibit visceral obesity (waist circumference ≥ 35 inches for women and ≥ 39 inches for men) and demonstrate signs of cardiometabolic dysfunction. Specifically, subjects were required to have elevated LDL cholesterol ≥ 130 mg/dl and/or elevated TG defined as TG ≥ 130 mg/dl. Additionally, subjects were required to have at least one of the following (unless subject had both elevated LDL and TG) HDL < 50 mg/dl for women and < 40 mg/dl for men blood glucose ≥ 100 mg/dl, HbA1C ≥ 5.7% or Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score defined as ≥ 2.0  included Pregnancy Lactation Recent changes in prescription medications, over-the-counter medications, medical foods, and nutritional supplements Recent or regular use of narcotics, investigational drugs, corticosteroids, anticoagulants, neuroactive medications, or medication or supplements relevant to hyperglycemia or hyperlipidemia Chronic use of over-the-counter medication which would interfere with study endpoints including laxatives and antacids Allergy or intolerance to study products Serious, unstable medical conditions including known infection with HIV, tuberculosis or hepatitis; cardiovascular disease; Diabetes Mellitus; autoimmune diseases; malignancy; psychiatric disease; substance abuse Abnormal laboratory findings Participating in or planning to begin a weight loss diet during the study period
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Myocardial Infarction Coronary Artery Disease Atrial Fibrillation Congestive Heart Failure Newly diagnosed type 2 diabetic patients (within the last 3 months) Participating in on-site the diabetes rehabilitation program at Cambridge Cardiac Rehab Deemed capable of high-intensity exercise  Known or suspected cardiovascular disease Diabetic end-organ damage Cerebrovascular disease Peripheral vascular disease Arthritis Joint disease Taking anti-glycemic medications Taking lipid lowering medications Ischemia, hypoxia, arrhythmia or hemodynamic instability during a stress test
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hepatitis B HBeAg negative Chronic HBV infection who are having HBV DNA-undetectable. ALT <40 IU/ml No Advanced fibrosis[LSM <14 KPa] TDF/ETV >1 year Clinical Relapse after stopping NA will be defined as HBV DNA>2000IU/ml and ALT > 80IU  HBeAg+ CHB Pregnancy Cirrhosis on biopsy or LSM >14 Co-infection HIV/HCV/HDV Immunosuppressive therapy Renal failure S.Bilirubin>2mg/dl Patient having neutropenia
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Type 1 Diabetes Hypoglycemia Physical Activity Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin Last A1C ≤ 9.9% Age: 18-65 years Duration of T1D: ≥ 2 years Using CSII via OmniPod® for at least 1 month (~50:50 bolus basal insulin ratio and on at least .25 units of insulin per kilogram body mass per day) Body mass index (BMI) < 30 kg/m2 In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations Willing to adhere to the protocol requirements for the duration of the study  Physician diagnosis of active diabetic retinopathy (proliferative or hemorrhage in past 6 months) that could potentially be worsened by exercise Physician diagnosis of peripheral neuropathy with insensate feet Physician diagnosis of autonomic neuropathy Medications: Beta blockers, agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives, Pramlinitide, any other hypoglycemic agent Participation in other studies involving administration of an investigational drug or device at the time of screening for the current study or planning to participate in another such study during participation in the current study Severe hypoglycemic event defined as the individual requiring third party assistance or hospitalization in the last 3 months
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 11.0-20.0,  Type1 Diabetes duration of T1D >3 years, CSII therapy for at least 1 year, good to moderate glycaemic control, as evidenced by HbA1c levels <8.5% (69 mmol/mol)  Subjects with eating disorders, food allergy, celiac disease and known diabetic complications